Complexa, Inc., a Pittsburgh, PA-based clinical-stage platform anti-inflammatory and fibrotic disease-focused biopharmaceutical company, completed a $13m Series B financing.
The round was led by JAFCO Life Science Investment, a part of JAFCO Co., Ltd., with participation from existing investors.
The company will use funds to further advance clinical development of two formulations of its lead compound CXA-10:
– an intravenous formulation which is currently in Phase I clinical trials for a form of acute kidney disease and
– an oral formulation for a form of chronic kidney disease for which an IND will be filed later this year.
Led by President and CEO Josh Tarnoff Complexa is a clinical stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. Its proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/function-related mediators that are designed to treat various diseases.